An Immune-Related Gene-Based Signature as Prognostic Tool in Ovarian Serous Cystadenocarcinoma

References

• Kurman RJ. WHO classification of tumours of female reproductive organs, 4th ed. France: IARC, Lyon; 2014. Available from: https://www.ncbi.nlm.nih.gov/nlmcatalog/101656343. Accessed July 19, 2021.
   Google Scholar
• Pogge von Strandmann E, Reinartz S, Wager U, Muller R. Tumor-host cell interactions in ovarian cancer: pathways to therapy failure. Trends Cancer. 2017;3:137–148. doi:10.1016/j.trecan.2016.12.005
   PubMed Web of Science ®Google Scholar
• Yin M, Li X, Tan S, et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016;126:4157–4173. doi:10.1172/JCI87252
   PubMed Web of Science ®Google Scholar
• Yin M, Shen J, Yu S, et al. Tumor-Associated Macrophages (TAMs): a critical activator in ovarian cancer metastasis. Onco Targets Ther. 2019;12:8687–8699. doi:10.2147/OTT.S216355
   PubMed Web of Science ®Google Scholar
• Kim J, Bae JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016;2016:6058147. doi:10.1155/2016/6058147
   PubMed Web of Science ®Google Scholar
• Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015;368:7–13. doi:10.1016/j.canlet.2015.07.039
   PubMed Web of Science ®Google Scholar
• Reinartz S, Schumann T, Finkernagel F, et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134:32–42. doi:10.1002/ijc.28335
   PubMed Web of Science ®Google Scholar
• Buonaguro FM, Pauza D, Tornesello ML, Hainaut P, Franco R, Marincola FM. Cancer diagnostic and predictive biomarkers. Biomed Res Int. 2014;2014:980163. doi:10.1155/2014/980163
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259–1271 e1211. doi:10.1016/j.cell.2017.10.001
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2012;41(D1):D991–D995. doi:10.1093/nar/gks1193
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19:A68–A77.
   Google Scholar
• Breuer K, Foroushani AK, Laird MR, et al. InnateDB: systems biology of innate immunity and beyond–recent updates and continuing curation. Nucleic Acids Res. 2013;41:D1228–D1233. doi:10.1093/nar/gks1147
   PubMed Web of Science ®Google Scholar
• Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337–344. doi:10.1111/j.0006-341X.2000.00337.x
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Tissue-based map of the human proteome. Science. 2015;347:6220. doi:10.1126/science.1260419
   Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–425. doi:10.1016/j.cels.2015.12.004
   PubMed Web of Science ®Google Scholar
• Xiao Y, Ma D, Zhao S, et al. Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin Cancer Res. 2019;25:5002–5014. doi:10.1158/1078-0432.CCR-18-3524
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218. doi:10.1186/s13059-016-1070-5
   PubMed Web of Science ®Google Scholar
• Cojocaru E, Parkinson CA, Brenton JD. Personalising treatment for high-grade serous ovarian carcinoma. Clin Oncol. 2018;30:515–524. doi:10.1016/j.clon.2018.05.008
   Web of Science ®Google Scholar
• Lee EK, Konstantinopoulos PA. Combined PARP and immune checkpoint inhibition in ovarian cancer. Trends Cancer. 2019;5:524–528. doi:10.1016/j.trecan.2019.06.004
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Odunsi K, Coukos G. Immune therapy opportunities in ovarian cancer. Am Soc Clin Oncol Educ Book. 2020;40:e228–e240.
   Google Scholar
• Rea K, Roggiani F, De Cecco L, et al. Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth. J Exp Clin Cancer Res. 2018;37:146. doi:10.1186/s13046-018-0796-1
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang X, Tang W, et al. miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-kappaB in high-grade serous ovarian carcinoma. Cell Death Differ. 2017;24:2089–2100. doi:10.1038/cdd.2017.129
   PubMed Web of Science ®Google Scholar
• Yamanoi K, Baba T, Abiko K, et al. Acquisition of a side population fraction augments malignant phenotype in ovarian cancer. Sci Rep. 2019;9:14215. doi:10.1038/s41598-019-50794-w
   PubMed Web of Science ®Google Scholar
• Li D, Sun Y, Kong X, et al. Association between a single nucleotide polymorphism in the 3ʹ-UTR of ARHGEF18 and the risk of nonidiopathic pulmonary arterial hypertension in Chinese population. Dis Markers. 2018;2018:2461845. doi:10.1155/2018/2461845
   PubMed Web of Science ®Google Scholar
• Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121:353–357. doi:10.1016/j.ygyno.2011.01.020
   PubMed Web of Science ®Google Scholar
• Jia R, Chai P, Wang S, et al. m(6)A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. Mol Cancer. 2019;18:161. doi:10.1186/s12943-019-1088-x
   PubMed Web of Science ®Google Scholar
• Nayak AP, Kapur A, Barroilhet L, Patankar MS. Oxidative phosphorylation: a target for novel therapeutic strategies against ovarian cancer. Cancers. 2018;10:337. doi:10.3390/cancers10090337
   PubMed Web of Science ®Google Scholar
• Zhu LY, Zhang WM, Yang XM, et al. Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal-epithelial transition. Cancer Lett. 2015;363:71–82. doi:10.1016/j.canlet.2015.04.002
   PubMed Web of Science ®Google Scholar
• Wade CA, Kyprianou N. Profiling prostate cancer therapeutic resistance. Int J Mol Sci. 2018;19:904. doi:10.3390/ijms19030904
   PubMed Web of Science ®Google Scholar
• Drakes ML, Stiff PJ. Regulation of ovarian cancer prognosis by immune cells in the tumor microenvironment. Cancers. 2018;10:302. doi:10.3390/cancers10090302
   PubMed Web of Science ®Google Scholar